Ablation‐Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular Carcinoma

BACKGROUND: Patients with unresectable hepatocellular carcinoma (HCC) who initially achieve disease control with atezolizumab plus bevacizumab (Atez/Bev) eventually develop progressive disease (PD). Treatment is usually shifted to subsequent systemic therapy, whereas ablation is rarely considered. We investigated whether ablation at PD could serve as a salvage option in selected patients after initial disease control with Atez/Bev. METHODS: From a multicenter database involving 16 institutions, we identified 186 patients with unresectable HCC who achieved partial response or stable disease with first-line Atez/Bev and subsequently developed PD between 2020 and 2025. Postprogression survival (PPS) and overall survival (OS) were compared between ablation and nonablation groups using propensity score matching (PSM). Multivariable Cox regression was performed for both OS and PPS. Inverse probability of treatment weighting (IPTW) and landmark analysis were used as sensitivity analyses. RESULTS: After PSM, 20 matched pairs were analyzed. OS tended to be longer in the ablation group than in the nonablation group (not reached vs. 25.7 months and p = 0.090). PPS was significantly longer in the ablation group (37.7 vs. 9.17 months and p = 0.043). In multivariable analyses adjusted for ALBI score and tumor number, ablation showed a trend toward improved OS (HR 0.393 and p = 0.063) and was associated with prolonged PPS (HR 0.335 and p = 0.035), although residual confounding limits causal inference. Sensitivity analyses showed consistent results. CONCLUSION: In selected patients who initially achieved disease control with Atez/Bev, ablation at PD may be a potential salvage approach associated with prolonged PPS. These exploratory and hypothesis-generating findings warrant prospective validation of ablation-based salvage strategies.

Authors

Institutions

Publication Details

Journal
Hepatology Research
Published
2026-05-11
DOI
https://doi.org/10.1111/hepr.70193
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Ablation‐Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular Carcinoma

Hideko Ohama, Yuki Kanayama, Kazuya Kariyama, Kazuhiro Nouso et al.
Hepatology Research
Hepatocellular Carcinoma Treatment and Prognosis
article

Ablation‐Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular Carcinoma

Hideko Ohama, Yuki Kanayama, Kazuya Kariyama, Kazuhiro Nouso, Hideyuki Tamai, Yutaka Yata, Fujimasa Tada, Akiko Wakuta, Michitaka Imai, Toru Ishikawa, Tomomitsu Matono, Satoshi Yasuda, Yoshihide Ueda, Takeshi Hatanaka, Kunihiko Tsuji, Hironori Tanaka, Koichi Takaguchi, Toshifumi Tada, Atsushi Hiraoka, Hidenori Toyoda, Akemi Tsutsui, Takashi Kumada, Atsushi Naganuma, Junpei Okamura, Ei Itobayashi, Kazunari Tanaka, Satoru Kakizaki, Masatoshi Kudo
article en

Abstract

BACKGROUND: Patients with unresectable hepatocellular carcinoma (HCC) who initially achieve disease control with atezolizumab plus bevacizumab (Atez/Bev) eventually develop progressive disease (PD). Treatment is usually shifted to subsequent systemic therapy, whereas ablation is rarely considered. We investigated whether ablation at PD could serve as a salvage option in selected patients after initial disease control with Atez/Bev. METHODS: From a multicenter database involving 16 institutions, we identified 186 patients with unresectable HCC who achieved partial response or stable disease with first-line Atez/Bev and subsequently developed PD between 2020 and 2025. Postprogression survival (PPS) and overall survival (OS) were compared between ablation and nonablation groups using propensity score matching (PSM). Multivariable Cox regression was performed for both OS and PPS. Inverse probability of treatment weighting (IPTW) and landmark analysis were used as sensitivity analyses. RESULTS: After PSM, 20 matched pairs were analyzed. OS tended to be longer in the ablation group than in the nonablation group (not reached vs. 25.7 months and p = 0.090). PPS was significantly longer in the ablation group (37.7 vs. 9.17 months and p = 0.043). In multivariable analyses adjusted for ALBI score and tumor number, ablation showed a trend toward improved OS (HR 0.393 and p = 0.063) and was associated with prolonged PPS (HR 0.335 and p = 0.035), although residual confounding limits causal inference. Sensitivity analyses showed consistent results. CONCLUSION: In selected patients who initially achieved disease control with Atez/Bev, ablation at PD may be a potential salvage approach associated with prolonged PPS. These exploratory and hypothesis-generating findings warrant prospective validation of ablation-based salvage strategies.

Hepatology Research
Wakayama Rosai Hospital (JP), Niigata Cancer Center Hospital (JP), Saiseikai Niigata Daini Hospital (JP), National Hospital Organization Takasaki Medical Center (JP), Ogaki Municipal Hospital (JP), Himeji Medical Center (JP), Hanwa Memorial Hospital (JP), Gunma Saiseikai Maebashi Hospital (JP), Kagawa University Hospital (JP), Teine Keijinkai Hospital (JP), Asahi General Hospital (JP), Ehime Prefectural Central Hospital (JP), Edogawa Hospital (JP), Kagawa Prefectural Central Hospital (JP), Takarazuka City Hospital (JP), Gifu Kyoritsu University (JP), Kobe University (JP), Kindai University (JP)
Good health and well-being
Openalex Percentile: Top 7%
Hepatocellular Carcinoma Treatment and Prognosis
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.